title: MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
abstract: The immunogenicity and reactogenicity of two influenza vaccines were evaluated in a randomised, double-blind trial in north-east Italy during winter 2005-2006. Of 238 adult subjects (18-60 years of age) with underlying chronic diseases, 120 received MF59-adjuvanted subunit vaccine (Sub/MF59) and 118 received conventional subunit vaccine (Subunit). At 4 weeks post-vaccination, geometric mean titres (GMT) were significantly (P<0.001) increased for both groups. For the A/H3N2 and B strains, significantly (P<0.02) higher GMT were reported for the Sub/MF59 group. The mean-fold increase in titre, the percentage of subjects with at least a four-fold titre increase and the seroprotection rate (>or=1:40) were also higher in the Sub/MF59 group, with the seroprotection rate and four-fold titre increase achieving significance (P=0.002 and P=0.02, respectively) for the A/H3N2 strain. Our results suggest that adults affected by chronic diseases can mount a satisfactory immune response to influenza vaccines, and that these vaccines are well tolerated. Addition of the MF59-adjuvant, however, enhances the immunogenicity of subunit influenza vaccine, conferring superior protection than a conventional subunit vaccine in this population, who are at high-risk of influenza-related complications.
authors: Department of Environmental Medicine and Public Health, Institute of Hygiene, University of Padua, Padua, Italy. vincenzo.baldo@unipd.it
authors: V
authors: V
authors: Baldo
authors: T
authors: T
authors: Baldovin
authors: A
authors: A
authors: Floreani
authors: A M
authors: AM
authors: Carraro
authors: R
authors: R
authors: Trivello
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D002908:Chronic Disease / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D053122:Influenza A Virus, H3N2 Subtype / Q000276:immunology*; D009981:Influenza B virus / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D007251:Influenza, Human / Q000150:complications / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D011136:Polysorbates / Q000009:adverse effects / Q000627:therapeutic use*; D012307:Risk Factors; D013185:Squalene / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D022223:Vaccines, Subunit / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D007252:Influenza Vaccines; C089950:MF59 oil emulsion; D011136:Polysorbates; D022223:Vaccines, Subunit; D013185:Squalene